Gradiant Bioconvergence, formerly known as Interpark Bioconvergence Corp. (IBCC),

is the one of earliest organizations developing patient-derived organoids (PDOs) in global scale.

Gradiant Bioconvergence's PDO banking with over 400 strains, co-culture platform with autologous T-cells, genetic-variation studies at whole-exome level, disease-modeling platform using CRISPR/Cas9

and novel growth-factors along ECMs for 3D culture provide leading opportunities for innovative partnership

in drug development, oncology research, and regenerative medicine.

2022

ㆍ04 Gradiant Bioconvergence founded



2021

ㆍ09 National Grant on organ-on-a-chip received
      (in collaboration with Seoul National University 

         College of Medicine)



2020

ㆍ08 Interpark Bioconvergence Corp. founded

ㆍ01 Collaboration agreement on organoid signed 

         with Institute of Molecular Biotechnology (IMBA)



2019

ㆍ12 License agreement signed with

         Hubrecht Organoid Technology (HUB)

ㆍ10 Precision Medicine Center founded
      (in collaboration with Severance Hospital)

ㆍ04 Collaboration agreement on decellularized   

         extracellular matrix (dECM) signed with POSTECH



2018

ㆍ02 MOU signed with Severance Hospital



2017

ㆍ04 Interpark Bioconvergence Center founded
     (in collaboration with International Vaccine 

        Insitute)